Read more from the company presentation here.
-----
And as I mentioned previously, NMTC has 5 must-see potential catalysts right now:
No. 1 NMTC Potential Catalyst - Insider Purchase By Company's CFO Could Be The Ultimate Bullish Signal
Insider Buying: CFO Ronald Mcclurg Acquires 50.9k Shares of NeuroOne Medical Technologies Corp...
On September 13, 2023, Ronald Mcclurg, the Chief Fi-nan-cial Officer (CFO) of NeuroOne Medical Technologies Corp (NASDAQ:NMTC), made a significant insider purchase of 50.9k shares of the company's st-ock. This move has caught the attention of market analysts as insider buying often signals confidence in the company's future prospects.
Ronald Mcclurg is a seasoned financial executive with a wealth of experience in the healthcare industry.
As the CFO of NeuroOne Medical Technologies Corp, he is responsible for the company's fi-nan-cial strategy and operations, playing a crucial role in its growth and development.
Over the past year, the insider has purchased a total of 50.9k shares and sold 0 shares. This recent acquisition by Ronald Mcclurg is the latest in a series of insider buys over the past year, indicating a strong belief in the company's potential.
The relationship between insider buying and selling and the st-ock price is often complex. However, it's generally accepted that insider buying particularly when it's on the scale of Ronald Mcclurg's recent purchase can be a bullish signal.
After all, insiders have a unique insight into the company's operations and future prospects. If they're willing to in-vest their own money in the company's st-ock, it suggests they believe the st-ock is undervalued or that the company has strong future growth potential.
Read the full article here.
-----
No. 2 NMTC Potential Catalyst - Company Update Shows Exciting Progress And A Near Future High On Potential
NeuroOne® Reports Third Quarter Fiscal Year 2023 Fi-nan-cial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal third quarter 2023 ended June 30, 2023.
Fiscal Third Quarter 2023 and Recent Business Updates
Financial Highlights:
- Product revenue of $630k in Q3 2023, compared to $32k in Q3 2022
- Collaboration revenue of $1.46Mn in first nine months of FY 2023, compared to $6k in first nine months of FY 2022
- Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023
Evo® sEEG:
- Completed limited launch at target centers by end of July; full launch with Zimmer Biomet expected by end of fiscal fourth quarter
- Positive user feedback received on product evaluation forms
- Initiation of new sites expected to ramp in fiscal fourth quarter
- Received first order for calendar 2024 product supply from Zimmer Biomet
OneRF™Ablation:
- Submitted 510(k) to FDA on June 8th
- Poster presentation on OneRF Ablation System preclinical study at the Neurological Disorders Summit (NDS 2023) in Italy
- Received feedback from FDA regarding 510(k) submission for OneRF Ablation System
Spinal Cord Stimulation Program:
- Completed 28 day animal implants of the Company’s thin film spinal cord stimulation paddle electrodes without any adverse events or neurological complications
- Filed a non-provisional patent for a novel conformable thin film paddle lead for spinal cord placement
Drug Delivery Program:
- Successfully completed proof of concept testing of drug delivery into the brain in a small animal model at the Mayo Clinic in Rochester, Minnesota
Dave Rosa, CEO of NeuroOne, commented, “The Company continues to execute on a number of commercial, development and financing objectives. We are now beginning to expand the commercial launch of our Evo sEEG electrode with Zimmer Biomet after a successful limited launch. In addition, we received encouraging feedback from the FDA regarding the Company’s recent 510(k) FDA submission of the OneRF Ablation System and believe our previous timelines remain on track. We are excited by the potential of our drug delivery system currently in development after recent testing at the Mayo Clinic in Rochester Minnesota. We also recently raised gross proceeds of $6.0Mn through a public offering which included new fundamental institutional in-vest-ors without having to offer warrants and $2.5Mn through the use of an ATM (at-the-market) facility. I am pleased with the Company’s continued execution on our strategic plan and I look forward to our future progress in the areas outlined.”
...
Read the full article here.
-----
No. 3 NMTC Potential Catalyst - A Low Float Can Create A Volatile Situation For This Explosive 4X Past Champ
According to the Yahoo Finance website, NMTC has a low float.
The website reports this profile to have approximately 20.43Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could more positive company news towards the end of 2023 help provide a breakout spark?
-----
No. 4 NMTC Potential Catalyst - Company Submits 510(k) Application To FDA For OneRF™ Ablation System
NeuroOne® Submits 510(k) Application to FDA for OneRF™ Ablation System
Potential for transformative improvement in neurosurgery as first known sEEG-guided RF system that records and ablates nervous tissue with the added benefit of temperature control
EDEN PRAIRIE, Minn., June 12, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today its submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for its OneRF™ Ablation System. This technology uses the already implanted sEEG electrodes to record brain activity and allow for ablation of nervous tissue when connected to a proprietary radio frequency (RF) generator. If cleared by the FDA, NeuroOne’s OneRF 510(k) submission represents the first step in bringing to market an innovative RF ablation system in the field of neurology and neurosurgery.
As the Company’s first therapeutic device, OneRF is a combination system that includes both diagnostic and therapeutic capabilities. The system utilizes a customized RF generator with real-time temperature monitoring capabilities, allowing clinicians to have greater control over temperature management during the ablation. Designed to both record brain activity and ablate nervous tissue using the same electrode, the system is designed to offer the potential for a safer clinical option for patients as well as lower costs by reducing the number of invasive procedures and hospital stays for patients. NeuroOne estimates the current brain ablation market to be at least $100Mn worldwide and growing rapidly, with the potential to grow multiple fold based on large addressable patient populations with unmet clinical needs.
Dave Rosa, CEO of NeuroOne, commented, “This is a monumental day for NeuroOne as it represents the first known FDA 510(k) submission of an sEEG electrode intended to record brain activity and also be used as an RF probe to ablate nervous tissue. In addition, it marks the Company’s first complete system combining hardware, software, and our novel electrode technology. Over the past few years, we have been excited with the feedback we have received from our advisory board as well as the performance of the system in animal feasibility studies. We also believe this system has applications beyond ablation of nervous tissue in the brain, offering a larger opp. than we initially envisioned. I am proud of our entire team and their efforts which allowed us to complete this before the end of June as planned.”
...
Read the full article here.
-----
No. 5 NMTC Potential Catalyst - Company Creates New Potential Revenue Stream With Key U.S. Commercial Launch
NeuroOne® Announces U.S. Commercial Launch of Evo® sEEG Electrodes
Evo sEEGs complementary to Zimmer Biomet’s robotic neurosurgery platform; strong market opp. for paired technologies
EDEN PRAIRIE, Minn., May 02, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the commercial launch of the Evo® sEEG electrode product line in the United States. Zimmer Biomet holds exclusive worldwide distribution rights to NeuroOne’s Evo Cortical and sEEG product lines, and the Evo product line is expected to utilize Zimmer Biomet’s ROSA One® Brain, a robotic platform that assists surgeons in planning and performing complex minimally invasive neurosurgical procedures.
Dave Rosa, CEO of NeuroOne, commented, “The commercial launch of the Evo sEEG platform represents one of the most impactful milestones in our Company’s history. Paired with Zimmer Biomet’s ROSA One Brain robotic platform and broad distribution network, we believe the Company is well positioned in the market given the synergies that exist between our novel thin film electrode platform and Zimmer Biomet’s robotic platform. Importantly, this new technology potentially provides NeuroOne with a steady and predictable new revenue stream. We expect to complete our initial case within the next 30 days.”
...
NeuroOne’s Evo sEEG electrode technology offers stereoelectroencephalography recording, brain stimulation and future capabilities for spinal cord stimulation, and ablation solutions targeted for patients suffering from epilepsy, chronic back pain, and Parkinson’s disease. The Evo® sEEG is the Company’s most advanced diagnostic electrode designed to be secure, precise, and less invasive, with proven placement accuracy and signal quality, and made in a mostly automated manufacturing process.
In October 2022, NeuroOne received FDA clearance to market its Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.
Read the full article here.
-----
NMTC Recap: 5 Potential Breakout Catalysts To Know Immediately
No. 1 - Insider Purchase By Company's CFO Could Be The Ultimate Bullish Signal
No. 2 - Company Update Shows Exciting Progress And A Near Future High On Potential
No. 3 - A Low Float Can Create A Volatile Situation For This Explosive 4X Past Champ
No. 4 - Company Submits 510(k) Application To FDA For OneRF™ Ablation System
No. 5 - Company Creates New Potential Revenue Stream With Key U.S. Commercial Launch
-----
Coverage is officially reinitiated on NMTC. When time permits, do this:
